Presentation TCT 2025 TCT 68: Early Initiation of PCSK9 Inhibitors in Acute STEMI: Safety and Efficacy Outcomes from the EARLY-STEMI Trial Presenter: Mohammed Ali October 28, 2025
Presentation TCT 2025 TCT 1004: Cardiovascular Outcomes of PCSK9 Inhibitor Use in Percutaneous Coronary Intervention Presenter: Grant William Reed October 27, 2025
Presentation TCT 2025 TCT 1261: Effect of PCSK9 Inhibitors on Coronary Plaque: A Meta-Analysis and Trial Sequential Analysis Presenter: Paulo Roberto Tartuce Filho October 27, 2025
News Daily News Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol Michael O'Riordan August 06, 2025
News Daily News No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits Michael O'Riordan July 14, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Conference News EAS 2025 Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM Yael L. Maxwell May 08, 2025
News Daily News Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention Michael O'Riordan May 07, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Daily News Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy Caitlin E. Cox April 14, 2025
News Conference News ACC 2025 ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a) L.A. McKeown April 10, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care Michael O'Riordan February 27, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025